After striking down the first proposal, the Drug Controller General India has allowed conducting the Phase II and III clinical trials under Dr Reddy’s Pharmaceuticals. According to Dr Reddy’s and Russian Direct Investment Fund, this will be the multi-centred and randomized drug control study. It includes safety and immunogenicity study as well. Previously, Sputnik V was tested on a small group of people and due to that, the trials were rejected by the DCGI. Now, it got approval as the test will be conducted on 40,000 people in India.